The future of diagnostics
Investors
Advancing the Future of Diagnostic Testing
Evora Diagnostics is developing an artificial intelligence-powered diagnostic platform designed to make disease detection faster, more accessible, and more affordable.
Built upon years of scientific research, clinical validation, and innovation originating at UCLA, Evora is creating technologies with the potential to transform how diagnostic testing is delivered across healthcare settings worldwide.
Investment Overview
A Platform Built for Scale
Evora is developing a flexible diagnostic platform capable of supporting multiple disease applications while addressing significant challenges in diagnostic accessibility, speed, and cost.
Our initial focus is Lyme disease, where current diagnostic limitations create substantial unmet need. Over time, the platform is designed to support expansion into additional disease categories including infectious diseases, cardiovascular conditions, metabolic disorders, allergy testing, and other diagnostic markets.
Why Evora
Key Investment Highlights
Proven Scientific Foundation
Built upon years of research, validation, and innovation developed through UCLA.
AI-Powered Platform
Combining machine learning, advanced biosensing, and rapid point-of-care testing technologies.
Large Unmet Need
Addressing diagnostic challenges that impact millions of patients each year.
Scalable Architecture
Designed to support multiple disease applications using a common technology platform.
Experienced Leadership
Led by scientists, engineers, healthcare advocates, and industry advisors with expertise in diagnostics, biotechnology, and commercialization.
Patient-Centered Mission
Inspired by real-world diagnostic challenges and focused on improving healthcare outcomes.
Traction & Validation
Built on Years of Research
Evora’s platform is supported by extensive scientific research, clinical evaluation, and technology development.
Peer-Reviewed Publications
Patents & Patent Applications
Patient Samples Evaluated
Minutes or Less for Results
Market Opportunity
Addressing a Growing Healthcare Need
Millions of patients experience delays in diagnosis due to limited access to testing, lengthy laboratory workflows, and diagnostic challenges associated with complex diseases.
Evora’s platform is designed to address these barriers by supporting faster, more accessible testing across a variety of healthcare settings, including hospitals, clinics, pharmacies, and laboratories.
As healthcare continues to move toward decentralized testing and personalized medicine, demand for rapid, reliable diagnostic solutions continues to grow.
Why Now
The Future of Diagnostics Is Changing
Several major trends are reshaping healthcare delivery:
- Expansion of point-of-care testing
- Increased adoption of artificial intelligence in healthcare
- Demand for faster clinical decision-making
- Rising focus on preventative and personalized medicine
- Continued need for improved diagnostic accessibility
Evora’s technology platform is designed to align with these shifts while supporting future diagnostic innovation across multiple disease areas.
Milestones
Development Progress
Achieved
UCLA research foundation established
Core technology development completed
Multiple validation studies completed
Scientific publications published
Patent portfolio established
Expansion opportunities identified across multiple disease areas
In Progress
Clinical validation studies
Regulatory preparation
Platform expansion initiatives
Commercialization planning
Strategic partnerships
Leadership
Guided by Experts
Evora Diagnostics brings together expertise across bioengineering, diagnostics, artificial intelligence, public health, healthcare advocacy, and biotechnology commercialization.
The leadership team combines scientific innovation with real-world healthcare experience, creating a unique perspective on the future of diagnostic testing.
Learn More About Evora Diagnostics
For investment-related inquiries, partnership opportunities, or additional information about Evora’s technology platform and development progress, please contact our team.